// App-Quantinova.ai

4654 : A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer (CRPC): A PCCTC trial.

Researchers

Presenter

  • Emmanuel S. Antonarakis

Principal Investigators

  • Elisabeth I. Heath

  • Edwin M. Posadas

  • Lyn M. Dyster

  • Michael Anthony Carducci

  • Michael Roger Harrison

  • Justine Yang Bruce

  • Evan Y. Yu

  • Steve Y. Cho

  • Gregory E. Wilding

  • Gerald J. Fetterly

  • David G. Hangauer

  • Min-Fun Rudolf Kwan

Medical Centers

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Roswell Park Cancer Institute, Buffalo, NY

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA

  • Duke Cancer Institute, Durham, NC

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

  • State University of New York at Buffalo, Buffalo, NY

  • Kinex Pharmaceuticals LLC, Buffalo, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

  • Solid malignancies

Biomarkers

  • Bone specific alkaline phosphatase

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • KX2-391

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved